Ophthotech Corporation (NASDAQ:OPHT) dropped -2.99% or -1.64 points to trade at $53.13 per share. As per the latest trading data available, the net money flow stood at $1.18 million as the shares received $2.86 million in upticks and gave away $1.68 million in downticks. The final up/down ratio was at 1.7. On a weekly basis, the stock has seen a change of 0.64%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 0. $1.35 million was the inflow in upticks and $0 million was the outflow in downticks. For the block trade, the net money flow was $1.35 million.
The stock has recorded a 20-day Moving Average of 0.51% and the 50-Day Moving Average is 9.94%. The company shares have rallied 5.37% in the past 52 Weeks. On December 30, 2015 The shares registered one year high of $80 and one year low was seen on September 29, 2015 at $35.72. The 50-day moving average is $50.47 and the 200 day moving average is recorded at $53.3. S&P 500 has rallied 1.93% during the last 52-weeks.
Ophthotech Corporation (NASDAQ:OPHT): The stock opened at $55.00 on Tuesday but the bulls could not build on the opening and the stock topped out at $55.09 for the day. The stock traded down to $53.05 during the day, due to lack of any buying support eventually closed down at $54.50 with a loss of -0.49% for the day. The stock had closed at $54.77 on the previous day. The total traded volume was 411,241 shares.
Currently the company Insiders own 12.2% of Ophthotech Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -26.17% . Institutional Investors own 90.6% of Ophthotech Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -26.65%. On the companys insider trading activities, Bolte Axel, director of Ophthotech Corp., executed a transaction worth $199,395 on June 3, 2016. A total of 3,500 shares were purchased at an average price of $56.97. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.